Drug
Atrasentan clinical trials
Also written ABT-627 and CHK-01.
- studies test it
- 21
- open now
- 3
- in phase 3
- 10
- first study started
- 2001
Keep track of what changes. Save the Atrasentan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
21 studies that test it; most in 2001 (5)
| Year | Studies |
|---|---|
| 2001 | 5 |
| 2002 | 3 |
| 2003 | 2 |
| 2006 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 10
- Phase 3
- 10
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 7
Novartis Pharmaceuticals (5) · Abbott (5) · AbbVie (2) · AbbVie (prior sponsor, Abbott) (2) · Eastern Cooperative Oncology Group (1) · SWOG Cancer Research Network (1) · Massachusetts General Hospital (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Zoledronic Acid (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses Atrasentan is read from its arms, and is right about nine times in ten.
Testing it · 21
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingPhase 3Novartis PharmaceuticalsNCT07498335Written as Drug: Atrasentan
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingPhase 3Novartis PharmaceuticalsNCT07850752Written as atrasentan
- Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)Not yet recruitingPhase 4University of Illinois at ChicagoNCT07820995Written as atrasentan
- Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedPhase 2Novartis PharmaceuticalsNCT05834738Written as Atrasentan
- Atrasentan in Patients With IgA NephropathyActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04573478Written as Atrasentan
- Atrasentan in Patients With Proteinuric Glomerular DiseasesActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04573920Written as Atrasentan
- Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney CancerCompletedPhase 2Eastern Cooperative Oncology GroupNCT00039429Written as atrasentan hydrochloride
- S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyCompletedPhase 3SWOG Cancer Research NetworkNCT00134056Written as atrasentan hydrochloride
- Atrasentan Spermatogenesis and Testicular FunctionCompletedPhase 2AbbVieNCT02118714Written as Atrasentan
- Study Of Diabetic Nephropathy With AtrasentanTerminatedPhase 3AbbVieNCT01858532Written as Atrasentan
- A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With NephropathyCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01399580Written as Atrasentan
- Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) InhibitorCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01356849Written as Atrasentan
- Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary AdenocarcinomaTerminatedPhase 2Vanderbilt-Ingram Cancer CenterNCT00653328Written as atrasentan hydrochloride
- Atrasentan in Treating Patients With Prostate CancerCompletedPhase 3AbbottNCT00046943Written as atrasentan hydrochloride
- Atrasentan and Zometa for Men With Prostate Cancer Metastatic to BoneCompletedPhase 2Massachusetts General HospitalNCT00181558Written as Atrasentan
- Correlation of Endothelial Function and Early Coronary Artery Disease in HumansCompletedPhase 3Mayo ClinicNCT00271492Written as Atrasentan
- Atrasentan in Treating Patients With Progressive or Recurrent Malignant GliomaCompletedPhase 1National Cancer Institute (NCI)NCT00017264Written as atrasentan hydrochloride
- A Long Term Safety Study With AtrasentanCompletedPhase 2/3AbbottNCT00127478Written as Atrasentan
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerCompletedPhase 3AbbottNCT00036556Written as Atrasentan
- Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical FailureCompletedPhase 2AbbottNCT00038662Written as Atrasentan
Codes
What other systems call Atrasentan · ClinicalTrials.gg INT006813
- MeSH (NLM) D000077868AtrasentanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) V6D7VK2215ATRASENTANConfirmed FDA, NLM, Wikidata
- RxNorm 282355One source Wikidata
- Wikidata Q125083atrasentanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61606AtrasentanOne source FDA
- DrugBank DB06199One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077868 | Atrasentan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | V6D7VK2215 | ATRASENTAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 282355 | — | One source Wikidata |
| Wikidata | Q125083 | atrasentan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61606 | Atrasentan | One source FDA |
| DrugBank | DB06199 | — | One source Wikidata |
Also registered as atrasentan hydrochloride (UNII E4G31X93ZA).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.